

Jihyun An

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2447057/publications.pdf>

Version: 2024-02-01

59
papers

2,113
citations

279487

23
h-index

233125

45
g-index

62
all docs

62
docs citations

62
times ranked

3122
citing authors

#	ARTICLE	IF	CITATIONS
1	HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. <i>Gut</i> , 2014, 63, 1325-1332.	6.1	319
2	MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 456.	3.4	241
3	Association between non-alcoholic fatty liver disease and cancer incidence rate. <i>Journal of Hepatology</i> , 2018, 68, 140-146.	1.8	185
4	Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: A need for surveillance. <i>Journal of Hepatology</i> , 2015, 62, 1092-1099.	1.8	114
5	Evaluation of Early-Stage Hepatocellular Carcinoma by Magnetic Resonance Imaging With Gadoteric Acid Detects Additional Lesions and Increases Overall Survival. <i>Gastroenterology</i> , 2015, 148, 1371-1382.	0.6	106
6	Current status and strategies for hepatitis B control in Korea. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 205-211.	4.5	89
7	Prevalence and Prediction of Coronary Artery Disease in Patients With Liver Cirrhosis. <i>Circulation</i> , 2014, 130, 1353-1362.	1.6	87
8	Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound. <i>Journal of Hepatology</i> , 2020, 72, 718-724.	1.8	86
9	microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression. <i>Oncotarget</i> , 2014, 5, 2792-2806.	0.8	85
10	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. <i>Gut</i> , 2016, 65, 1042-1051.	6.1	76
11	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. <i>Gut</i> , 2016, 65, 852-860.	6.1	70
12	Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis. <i>Hepatology</i> , 2019, 69, 1599-1613.	3.6	70
13	Stereotactic body radiation therapy for small (≤ 5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 506-515.	4.5	52
14	Chronic hepatitis B infection and non-hepatocellular cancers: A hospital registry-based, case-control study. <i>PLoS ONE</i> , 2018, 13, e0193232.	1.1	42
15	Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. <i>Hepatology</i> , 2017, 66, 772-783.	3.6	37
16	Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes. <i>Journal of Hepatology</i> , 2019, 71, 91-103.	1.8	37
17	Reappraisal of serum alpha-fetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. <i>Liver International</i> , 2015, 35, 232-239.	1.9	35
18	GÎ±12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4Î± inactivation, which causes c-Met induction. <i>Oncotarget</i> , 2015, 6, 19055-19069.	0.8	35

#	ARTICLE	IF	CITATIONS
19	Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 160-169.	4.5	33
20	Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2923-2931.	1.1	29
21	G12 gep oncogene inhibits FOXO1 in hepatocellular carcinoma as a consequence of miR-135b and miR-194 dysregulation. <i>Cellular Signalling</i> , 2014, 26, 1456-1465.	1.7	28
22	The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection. <i>PLoS ONE</i> , 2018, 13, e0198138.	1.1	28
23	Characterization of Hepatocellular Carcinoma Patients with FGF19 Amplification Assessed by Fluorescence in situ Hybridization: A Large Cohort Study. <i>Liver Cancer</i> , 2019, 8, 12-23.	4.2	27
24	Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study. <i>BMC Cancer</i> , 2021, 21, 11.	1.1	20
25	Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area. <i>Liver International</i> , 2016, 36, 1351-1361.	1.9	19
26	Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas. <i>Hepatology</i> , 2022, 75, 997-1011.	3.6	16
27	A Patient-Based Nomogram for Predicting Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1787-1794.e1.	0.2	13
28	Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 144-150.	4.5	13
29	PET-Based Radiogenomics Supports mTOR Pathway Targeting for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1821-1831.	3.2	12
30	Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial. <i>BMC Gastroenterology</i> , 2017, 17, 15.	0.8	11
31	Drug rash with eosinophilia and systemic symptoms syndrome following cholestatic hepatitis A: a case report. <i>The Korean Journal of Hepatology</i> , 2012, 18, 84.	1.5	10
32	On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. <i>Liver International</i> , 2022, 42, 59-68.	1.9	10
33	Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis. <i>Journal of Medical Virology</i> , 2016, 88, 1576-1586.	2.5	9
34	Postresection Period-Specific Hazard of Recurrence as a Framework for Surveillance Strategy in Patients with Hepatocellular Carcinoma: A Multicenter Outcome Study. <i>Liver Cancer</i> , 2022, 11, 141-151.	4.2	7
35	The clinical behavior and survival of patients with hepatocellular carcinoma and a family history of the disease. <i>Cancer Medicine</i> , 2019, 8, 6624-6633.	1.3	6
36	Prognostic Molecular Indices of Resectable Hepatocellular Carcinoma: Implications of S100P for Early Recurrence. <i>Annals of Surgical Oncology</i> , 2021, 28, 6466-6478.	0.7	6

#	ARTICLE	IF	CITATIONS
37	Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 2499-2510.	1.9	6
38	Focal type of peliosis hepatis. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 398.	4.5	6
39	A Case of Severe Community-acquired <i>Acinetobacter baumannii</i> Pneumonia with Bacteremia. <i>Infection and Chemotherapy</i> , 2012, 44, 71.	1.0	5
40	Histological expression of methionine adenosyl transferase (MAT) 2A as a post-surgical prognostic surrogate in patients with hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 892-901.	0.8	5
41	A Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 555-563.	0.6	5
42	Multiplex polymerase chain reaction test for the diagnosis of acute viral hepatitis A. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 397.	4.5	5
43	Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 504-513.	0.2	4
44	Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000-Korean outcome study. <i>Journal of Viral Hepatitis</i> , 0, , .	1.0	3
45	Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2021, , .	4.5	2
46	Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials. <i>Hepatology Communications</i> , 2022, 6, 2886-2900.	2.0	2
47	Surveillance for hepatocellular carcinoma in chronic hepatitis B virus infection: for whom. <i>Hepatic Oncology</i> , 2015, 2, 225-229.	4.2	1
48	Response to Letter Regarding Article, "Prevalence and Prediction of Coronary Artery Disease in Patients With Liver Cirrhosis: A Registry-Based Matched Case-Control Study." <i>Circulation</i> , 2015, 132, e19.	1.6	1
49	Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma. <i>Hepatology International</i> , 2017, 11, 209-219.	1.9	1
50	Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0238078.	1.1	1
51	Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years) Tj ETQq1 1 0.784314 rg	1.0	1
52	Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study. <i>Gut</i> , 2021, , gutjnl-2021-325844.	6.1	0
53	A Case of Acute Eosinophilic Pneumonia after Hematopoietic Stem Cell Transplantation. <i>Tuberculosis and Respiratory Diseases</i> , 2011, 71, 459.	0.7	0
54	Reply: Letter to the Editor regarding "Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis." <i>Clinical and Molecular Hepatology</i> , 2022, , .	4.5	0

#	ARTICLE	IF	CITATIONS
55	The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2022, 22, 40-50.	0.3	0
56	Title is missing!. , 2020, 15, e0238078.		0
57	Title is missing!. , 2020, 15, e0238078.		0
58	Title is missing!. , 2020, 15, e0238078.		0
59	Title is missing!. , 2020, 15, e0238078.		0